Allen Samuels, MD
Rheumatology · Erie, PANPI 1811033764
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,600 of the $2,716 with a category attached, or 95.7%. Boehringer Ingelheim accounts for 95.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $2,600 and has fallen 98.3% since, to $44 in 2025. That places this record below the midpoint for rheumatology clinicians in PA, where the typical reported total is $1,951.
Across 7 payments — averaging $387.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Teva Pharmaceuticals USA, Inc.$44
- Aurinia Pharma U.S., Inc.$39
- Pfizer$20
- Johnson & Johnson$12
What the payments were for
- Consulting fees$2,60096%
- Food & beverage$763%
- Education$391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $2,600 |
| Teva Pharmaceuticals USA, Inc. | 1 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $39 |
| Pfizer | 1 | $20 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$2,600
How this compares
$2,716 in reported general payments places this provider in the 50th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 25 | $235,652 |
| RinvoqUpadacitinib | 31 | $218,030 |
| HumiraAdalimumab | 31 | $205,747 |
| Enbrel SureclickEtanercept | 20 | $147,748 |
| ProliaDenosumab | 38 | $64,440 |
| OrenciaAbatacept/Maltose | 16 | $63,830 |
| BenlystaBelimumab | 12 | $27,538 |
| Hydroxychloroquine Sulfate | 337 | $16,871 |
| Risedronate Sodium | 58 | $6,285 |
| Etodolac ErEtodolac | 30 | $4,355 |
| Leucovorin Calcium | 19 | $3,900 |
| Leflunomide | 41 | $3,009 |
| Celecoxib | 57 | $2,400 |
| Gabapentin | 126 | $2,075 |
| Metaxalone | 20 | $1,984 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Erie
- Charles HerbstErie$32K
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.